ArQule regains global rights to AKT program from Daiichi
The retrieval of rights is based on Daiichi’s decision to conclude a license and co-commercialization agreement with ArQule. ArQule chief medical officer Brian Schwartz said, "AKT, also known
SK bioscience is set to lead the Gates Foundation-fundedResearch Optimization & Trial Outcome Recommender (ROTOR) project, an AI-based platform aimed at reducing uncertainty in vaccine-development decisions.